logo-loader
viewArcadia Biosciences Inc

Arcadia Biosciences launches $7.5 million registered direct offering

The capital will be used for general corporate purposes, including a hemp germplasm acquisition, breeding and research activities and the scale-up of the GoodWheatTM product

money
Investors will purchase of 1,489,575 shares of Arcadia common stock at $5.035 per share

Arcadia Biosciences Inc (NASDAQ:RKDA) announced Thursday a $7.5 million registered direct offering with several accredited and institutional investors.

The agricultural biotech company said it will use the capital for general corporate purposes, including a hemp germplasm (DNA of the hemp seed) acquisition, breeding and research activities, the scale-up of its GoodWheatTM product, and for general and administrative expenses.

Under the offering priced at-the-market that’s expected to close on Friday, investors will purchase of 1,489,575 shares of Arcadia’s common stock at $5.035 per share, according to a statement.

READ: Shares of Arcadia Biosciences jump after White House streamlines approval process of new GMO crops

Additionally, Arcadia has also agreed to issue to the investors unregistered warrants to purchase up to 1,489,575 shares of common stock at an immediately exercisable price of $5 per share. The warrants will expire five and a half years from the issue date.

Arcadia, based in Davis, California, develops high-value food ingredients and nutritional oils that aim to meet the demand for healthier diets. It also produces a GMO soybean.

The company’s stock recently traded down 33% to $3.95 a share following the company’s announcement.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Arcadia Biosciences Inc

Price: 4.15 USD

NASDAQ:RKDA
Market: NASDAQ
Market Cap: $35.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences records some big wins in the 3rd Quarter

Arcadia Biosciences (NASDAQ: RKDA) CEP Matt Plavan joined Proactive’s Steve Darling to discuss the company’s third-quarter results. Plavan also discussed some of the company highlights during that quarter including the latest on their research facilities. Plavan also discussed their hemp...

4 days ago

2 min read